.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

PHOSLYRA Drug Profile

« Back to Dashboard
Phoslyra is a drug marketed by Fresenius Medcl and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in seventeen countries.

The generic ingredient in PHOSLYRA is calcium acetate. There are two hundred and fifty-four drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the calcium acetate profile page.

Summary for Tradename: PHOSLYRA

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: PHOSLYRA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Medcl
PHOSLYRA
calcium acetate
SOLUTION;ORAL022581-001Apr 18, 2011RXYes8,591,938► subscribeY ► subscribe
Fresenius Medcl
PHOSLYRA
calcium acetate
SOLUTION;ORAL022581-001Apr 18, 2011RXYes8,592,480► subscribe ► subscribe
Fresenius Medcl
PHOSLYRA
calcium acetate
SOLUTION;ORAL022581-001Apr 18, 2011RXYes9,089,528► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PHOSLYRA

Drugname Dosage Strength RLD Submissiondate
calcium acetateOral Solution667 mg/5 mLPhoslyra12/5/2013

International Patent Family for Tradename: PHOSLYRA

Country Document Number Estimated Expiration
Poland2048948► subscribe
Canada2658465► subscribe
Australia2007275606► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PHOSLYRA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB03/033United Kingdom► subscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
2014 00050Denmark► subscribePRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
2008006Lithuania► subscribePRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc